Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting.
-
Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters.
-
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
-
Myriad Genetics announces the launch of the Precise MRD test with a select number of oncology practices for patients with breast cancer.
-
Data presented at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests.
-
Myriad advances Precise MRD toward a March 2026 launch, backed by new breast and colorectal cancer data showing ultrasensitive ctDNA detection.
-
Burning Rock Announces Founder’s Purchase of Its ADSs
-
Burning Rock Announces Results of 2025 Annual General Meeting
-
Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025
-
Burning Rock Reports Third Quarter 2025 Financial Results